Alpha memo: glucose patients diabetes accord endpoint split

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reset the scope to focus exclusively on the TyG index and CKD risk in women (Receipt 2).
2. Remove the claims regarding BP-target intensification and CV outcomes, as Receipt 1 provides no evidence to support a signal; it only frames a question.

Major issues

• The memo attempts to synthesize two unrelated signals (BP/Glucose CV outcomes and TyG/CKD sex disparities) into a single 'alpha' without a coherent biological or clinical link other than both using the ACCORD trial dataset.
• Receipt 1 is an editorial/commentary that poses a question but provides no data or results, meaning the first half of the central claim is entirely unsupported by the provided evidence bundle.

Reviewer note

The manuscript fails the basic requirement of making one bounded research signal clear. Instead, it bundles two disparate observations—one being a data-backed finding on TyG and CKD in women, and the other being a rhetorical question from an editorial about BP targets. There is no synthesis here, only a juxtaposition of two different endpoints (CV vs CKD) and two different exposures (BP targets vs TyG index). Because the 'alpha' claim relies on a source (Receipt 1) that contains no actual results, the central thesis is materially unsupported. The memo requires a complete scope reset to focus on the valid signal in Receipt 2.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis